Mansoori S, Noei A, Maali A, Seyed-Motahari S, Sharifzadeh Z
Cancer Cell Int. 2024; 24(1):304.
PMID: 39227937
PMC: 11370086.
DOI: 10.1186/s12935-024-03479-y.
Egli L, Kaulfuss M, Mietz J, Picozzi A, Verhoeyen E, Munz C
Exp Hematol Oncol. 2024; 13(1):51.
PMID: 38745250
PMC: 11092129.
DOI: 10.1186/s40164-024-00522-6.
Nwozichi C, Ogunmuyiwa A, Ojewale M
Asia Pac J Oncol Nurs. 2024; 11(2):100367.
PMID: 38304228
PMC: 10831260.
DOI: 10.1016/j.apjon.2023.100367.
Chen R, Chen L, Wang C, Zhu H, Gu L, Li Y
Front Oncol. 2023; 13:1288383.
PMID: 38115906
PMC: 10728652.
DOI: 10.3389/fonc.2023.1288383.
Mian A, Wei W, Hamilton B, Winter A, Khouri J, Pohlman B
Bone Marrow Transplant. 2023; 58(5):590-593.
PMID: 36774431
DOI: 10.1038/s41409-023-01934-4.
Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date.
Mann H, Comenzo R
Onco Targets Ther. 2022; 15:799-813.
PMID: 35912273
PMC: 9327779.
DOI: 10.2147/OTT.S305429.
Role of bridging therapy during chimeric antigen receptor T cell therapy.
Bhaskar S, Dholaria B, Sengsayadeth S, Savani B, Oluwole O
EJHaem. 2022; 3(Suppl 1):39-45.
PMID: 35844303
PMC: 9175845.
DOI: 10.1002/jha2.335.
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells.
Agarwalla P, Ogunnaike E, Ahn S, Froehlich K, Jansson A, Ligler F
Nat Biotechnol. 2022; 40(8):1250-1258.
PMID: 35332339
PMC: 9376243.
DOI: 10.1038/s41587-022-01245-x.
The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.
Mohseni Y, Tung S, Dudreuilh C, Lechler R, Fruhwirth G, Lombardi G
Front Immunol. 2020; 11:1608.
PMID: 32793236
PMC: 7393941.
DOI: 10.3389/fimmu.2020.01608.
ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy.
Brown A, Jindani I, Melancon J, Erfe R, Westin J, Feng L
Am J Respir Crit Care Med. 2020; 202(8):1184-1187.
PMID: 32530704
PMC: 7560798.
DOI: 10.1164/rccm.202002-0286LE.
Value and affordability of CAR T-cell therapy in the United States.
Fiorenza S, Ritchie D, Ramsey S, Turtle C, Roth J
Bone Marrow Transplant. 2020; 55(9):1706-1715.
PMID: 32474570
DOI: 10.1038/s41409-020-0956-8.
Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia.
Barsan V, Ramakrishna S, Davis K
Curr Oncol Rep. 2020; 22(2):11.
PMID: 31997022
DOI: 10.1007/s11912-020-0875-2.
Cost-effectiveness of Tisagenlecleucel vs Standard Care in High-risk Relapsed Pediatric Acute Lymphoblastic Leukemia in Canada.
Furzer J, Gupta S, Nathan P, Schechter T, Pole J, Krueger J
JAMA Oncol. 2020; 6(3):393-401.
PMID: 31971547
PMC: 6990832.
DOI: 10.1001/jamaoncol.2019.5909.
The First Year of HemaSphere and Many More to Come.
Engert A, Cools J
Hemasphere. 2019; 2(6):e161.
PMID: 31723799
PMC: 6745960.
DOI: 10.1097/HS9.0000000000000161.
Disparities in Survival and Health Outcomes in Childhood Leukemia.
Winestone L, Aplenc R
Curr Hematol Malig Rep. 2019; 14(3):179-186.
PMID: 31073772
DOI: 10.1007/s11899-019-00515-x.
Mechanisms of resistance to CAR T cell therapy.
Shah N, Fry T
Nat Rev Clin Oncol. 2019; 16(6):372-385.
PMID: 30837712
PMC: 8214555.
DOI: 10.1038/s41571-019-0184-6.
Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.
Ittershagen S, Ericson S, Eldjerou L, Shojaee A, Bleickardt E, Patel M
Curr Hematol Malig Rep. 2019; 14(1):47-55.
PMID: 30666506
DOI: 10.1007/s11899-019-0498-6.
